Technicals

Why MINDBODY (MB) Could Be an Impressive Growth Stock

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses. […]

Technicals

Looking for a Top Momentum Stock? 3 Reasons Why Bank Mutual Corp. (BKMU) is a Great Choice

Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term. […]

Technicals

Is Hackett Group (HCKT) a Great Growth Stock?

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses. […]

Technicals

Looking for a Growth Stock? Why It is Time to Focus on Barracuda Networks (CUDA)

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses. One such company that might be well-positioned for future earnings growth is Barracuda Networks, Inc […]

Technicals

3 Reasons Why FMC Corp (FMC) is a Great Momentum Stock

Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term […]

Technicals

What Makes KCAP Financial (KCAP) a Strong Sell?

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio. […]

Technicals

Time to Focus on Fabrinet (FN) for Strong Earnings Growth Potential

Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, so it is important to find companies which are still seeing strong growth prospects in their businesses. One such company that might be well-positioned for future earnings growth is Fabrinet FN . […]

Stock Analysts

Infosys (INFY) to Upgrade Council of Europe’s HR Platform

Premium technology services and consulting firm Infosys INFY recently announced that it has deployed an upgraded human resource management and payroll solutions for the Council of Europe. This 18-month project strengthens Infosys’ decade-old partnership with the renowned human rights organization. Per the deal, Infosys will be managing and customizing the cumbersome HR processes of its client by deploying its Oracle PeopleSoft Human Capital Management 9.2 […]

Stock Analysts

Sanofi Opts into Alnylam’s Fitusiran Hemophilia Program in U.S.

Alnylam Pharmaceuticals, Inc. ALNY announced that Genzyme, the specialty care global business unit of Sanofi SNY , has elected to opt in to co-develop and co-commercialize fitusiran in the United States, Canada and Western Europe. Notably, Fitusiran is an investigational RNA interference (RNAi) therapeutic being developed for the treatment of hemophilia and rare bleeding disorders (RBD). […]